DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd has a price-to-earnings (PE) ratio of 22.2 in the Healthcare sector.

What is the market capitalisation of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd has a market capitalisation of approximately ₹39 crore.

Sandu Pharmaceuticals Ltd

SANDUPHARMACEUTICALSLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

A steady, established business

52W₹30

₹58-106%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹39 Cr

P/E Ratio

22.20Fair

P/B Ratio

1.12

EPS

₹1.60

Book Value

₹36.34

ROE

4.13%Weak

ROCE

5.47%Weak

Dividend Yield

1.97%

Debt / Equity

0.01Low

Face Value

₹10.00

52W High

₹58.28

52W Low

₹30.00

Sector

Healthcare

Industry

Pharmaceuticals

Expensive

None moatMedium uncertainty

Fair value estimate

₹34

No recent traded price

BearFair valueBull

₹29₹34₹39

/100

Business quality — Watch the fundamentals

Growth 50Profitability 1Efficiency 0Valuation 85

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Weak returns on equity (4%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

22.2Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

4.1%Weak

Above 15% is considered healthy for Indian equities

ROCE

5.5%Weak

Above 18% means capital is working hard

Debt/Eq

0.01Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹39 Cr

P/B

1.12

EPS

₹1.60

Div Yield

1.97%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Reasonable

P/E 22.2×

Growth

Slow

+1% rev CAGR

Profitability

Modest

4.1% ROE

Financial health

Rock solid

D/E 0.01

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+1.0%

+2.8%

10Y

+5.7%

Profit

+1.7%

+8.0%

10Y

+11.5%

EPS

+0.0%

+2.6%

10Y

+7.5%

Profile

Pros

Company is almost debt free.
Stock is trading at 0.91 times its book value
Company has been maintaining a healthy dividend payout of 52.5%
Company's working capital requirements have reduced from 53.8 days to 42.0 days

Watch-outs

Cons

The company has delivered a poor sales growth of 3.54% over past five years.
Promoter holding is low: 37.8%
Company has a low return on equity of 3.85% over last 3 years.
Promoter holding has decreased over last 3 years: -14.6%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

38%

Promoter

Promoters

37.8%0.00

Public

37.0%-0.03

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

25.2%

Total shareholders

10,298+14 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter37.79%

DII0.01%

Public36.98%

Others25.22%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1985, Sandu Pharmaceuticals Ltd is a manufacturer of Ayurvedic Medicines.[1]